JP2012211164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211164A5
JP2012211164A5 JP2012138485A JP2012138485A JP2012211164A5 JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5 JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5
Authority
JP
Japan
Prior art keywords
val xaa
xaa pro
xau
isomer
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012138485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012211164A (ja
Filing date
Publication date
Priority claimed from US08/896,394 external-priority patent/US6143721A/en
Application filed filed Critical
Publication of JP2012211164A publication Critical patent/JP2012211164A/ja
Publication of JP2012211164A5 publication Critical patent/JP2012211164A5/ja
Pending legal-status Critical Current

Links

JP2012138485A 1997-07-18 2012-06-20 ドラスタチン15誘導体 Pending JP2012211164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 1997-07-18
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008315263A Division JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Publications (2)

Publication Number Publication Date
JP2012211164A JP2012211164A (ja) 2012-11-01
JP2012211164A5 true JP2012211164A5 (enExample) 2013-01-10

Family

ID=25406130

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2012138485A Pending JP2012211164A (ja) 1997-07-18 2012-06-20 ドラスタチン15誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU2001227375A1 (en) * 2000-02-08 2001-08-20 Herbert T. Nagasawa N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
CA2479764C (en) * 2002-03-22 2013-07-30 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
EP1828776A4 (en) * 2004-12-09 2010-03-17 Eisai R&D Man Co Ltd TUBULINISOTYPE SEARCH IN CANCER THERAPY WITH HEMIASTERLINANALOGES
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Birドメイン結合化合物
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
ATE543835T1 (de) 2007-07-16 2012-02-15 Genentech Inc Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
SG181797A1 (en) * 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
EP4400121A1 (en) 2021-09-03 2024-07-17 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) * 1991-08-09 2002-03-19 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide derivative
US5448045A (en) 1992-02-26 1995-09-05 Clark; Paul C. System for protecting computers via intelligent tokens or smart cards
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE69320339T2 (de) * 1992-05-20 1998-12-17 Basf Ag, 67063 Ludwigshafen Derivate des Dolastatin
AU679479B2 (en) * 1992-12-16 1997-07-03 Basf Aktiengesellschaft Dolostatin analog
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US6104815A (en) 1997-01-10 2000-08-15 Silicon Gaming, Inc. Method and apparatus using geographical position and universal time determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Similar Documents

Publication Publication Date Title
JP2011511805A5 (enExample)
JP2016538254A5 (enExample)
JP2007269812A5 (enExample)
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
ES2603058T3 (es) Láminas, esponjas y bayetas revestidas de un tratamiento antimicrobiano
JP2013542247A5 (enExample)
JP2012530060A5 (enExample)
NZ593524A (en) A nonapeptide with anti-tumour activity
JP2013509429A5 (enExample)
JP2009535462A5 (enExample)
JP2013534248A5 (enExample)
JP2008513467A5 (enExample)
JP2013520405A5 (enExample)
JP2011137005A5 (enExample)
EA201071409A1 (ru) Новые соли (4-{[(5-{[(3-хлорфенил)метил]окси}-2-метилфенил)карбонил]амино}-3-метилфенил)уксусной кислоты
CL2008003322A1 (es) Compuestos derivados de acidos de ciclobutanoamino, moduladores de receptores s1p; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de artritis, enfermedades autoinmunes, diabetes tipo i, enfermedad pulmonar obstructiva cronica, entre otras.
BR112012017691A2 (pt) nova composição
JP2012529293A5 (enExample)
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
JP2008013542A5 (enExample)
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
ATE387910T1 (de) Verfahren zur verbesserung der bioverfügbarkeit von ospemifen
JP2010265269A5 (enExample)
JP2010531373A5 (enExample)